

A practical guide for providers to help patients find Aurovela Fe 1/20 in stock. Five actionable steps, alternatives, and workflow tips.
Patients are showing up to appointments — or calling your office in a panic — because their pharmacy can't fill their Aurovela Fe 1/20 prescription. As a provider, you're in a unique position to intervene effectively. This guide gives you a practical, step-by-step workflow for helping patients maintain uninterrupted access to their Norethindrone Acetate/Ethinyl Estradiol 1 mg/20 mcg contraception.
For background on the supply situation, see our companion briefing: Aurovela Fe 1/20 shortage: what providers need to know in 2026.
As of early 2026, Aurovela Fe 1/20 (manufactured by Aurobindo Pharma) is still in production but inconsistently stocked at major chain pharmacies. The issue stems from formulary changes at large pharmacy chains rather than a true manufacturing shortage.
Key availability facts:
Understanding the root causes helps you counsel patients effectively and set expectations:
The single most impactful action you can take. Instead of specifying "Aurovela Fe 1/20," write:
Norethindrone Acetate/Ethinyl Estradiol 1 mg/20 mcg with Ferrous Fumarate, 28-day pack
This allows the dispensing pharmacist to fill with any AB-rated equivalent — Aurovela, Junel, Microgestin, Blisovi, or Larin — based on current stock. Avoid DAW (Dispense as Written) designations unless the patient has a documented allergy or adverse reaction to specific inactive ingredients.
Use Medfinder for Providers to check real-time pharmacy inventory at the point of prescribing. A quick search can tell you which pharmacies near your patient's home or work currently have their medication in stock. This prevents the frustrating cycle of the patient visiting multiple pharmacies or making multiple phone calls.
Consider building this check into your standard prescribing workflow, particularly for medications with known availability issues.
Take 60 seconds during the visit to explain:
You can also share patient-facing resources like our guide on alternatives to Aurovela Fe 1/20.
For patients with a history of fill difficulties, consider:
When a patient calls about a fill problem, your staff can:
If the entire Norethindrone Acetate/Ethinyl Estradiol 1 mg/20 mcg class is unavailable (rare but possible), consider these alternatives based on patient profile:
For detailed information on each alternative, see our patient-facing guide on alternatives to Aurovela Fe 1/20.
Create a reference sheet for your clinical staff listing:
If your EHR allows customized prescription favorites, create templates using generic names rather than brand names for all commonly prescribed oral contraceptives. Include a note field for "any AB-rated generic acceptable."
Ask your front desk or nursing staff to log when patients report fill difficulties by medication and pharmacy. Over time, this data can help you proactively route prescriptions to pharmacies with better track records for specific medications.
Send patients links to these resources via patient portal messages or printed handouts:
The Aurovela Fe 1/20 availability situation requires a proactive approach from prescribers. Generic-name prescribing, real-time inventory checking through Medfinder for Providers, and patient education are the three highest-impact interventions. By building these into your workflow, you can prevent contraceptive gaps and reduce patient anxiety around medication access.
For cost-related guidance to share with patients or incorporate into assistance program referrals, see our provider guide on how to help patients save money on Aurovela Fe 1/20.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.